Bmc Cancer

The most recent articles from: Bmc Cancer May 2007

Bmc Cancer · May 2007

Multicenter Study

Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study.

To evaluate the efficacy and the toxicity of front line FOLFOX4 combined with bevacizumab in patients with metastatsic CRC (mCRC). ⋯ The combination of FOLFOX4/bevacizumab appears to be highly effective, well tolerated and merits further evaluation in patients with mCRC.

explore further… mark as read…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.